close

MY CHINA PLUS is the first Virtual Warehouse all-in-one to distribute on Chinese / Asian markets in an easy, effective and economical way in Shanghai New Free Trade Zone.

The solution, based on Food & Beverages distribution platforms activities and experience, is designed for manufacturers / distributors who wish to have direct support in their business operations, promotion and distribution also without the need for a corporate presence in China.

How does My China B2B PLUS?

  • 1) SETUP: with My China B2B support, the company defines the space and the type of products that will store (temperature controlled, Fresh, Frozen)

NB: The warehouse is into the Shanghai FREE TRADE ZONE. This allows that stored products to pay duties and taxation only when they have been sold!

  • 2) SEND PRODUCTS: The company sends by sea the items to be stored in the warehouse in China.
    • For products without Chinese labeling:
      • Simultaneously with the product sending, are activated for the incoming products, the procedures with the Chinese authorities for obtaining the Chinese labels.

      • Upon arrival and during storage, products labeling  with Chinese labels

NB This allows to sell immediately the products on the Chinese market (competitive advantage - Ready to Sell) and also be used in fairs / exhibitions as Chinese products, with a big reduction of costs if the same products are shipped from their own country to the same exhibition (about 800 € every 100 kg).

  • 3) MANAGEMENT: Remote monitoring of Virtual Warehouse Platform by My China B2B PLUS Tools.
    • Movement Managing of the stored goods  (in / out)
    • Transfer / transport to other Chinese locations and Asian nations (for fairs, events, sales).
    • Tours of potential buyers (Showroom) to touch the stored products before buy.
    • My China Desk support for all logistics management activities and business relationships with potential buyers / distributors
    • Storing also in other Chinese locations (as needed)

Benefits for MY CHINA PLUS customers :

  • Only one point of contact in english / chinese language for all procedures (logistics, distribution, commercial) and documentation (invoices, documents, etc. ..)
  • Cutting costs (and time) about fairs, exhibitions, workshops and tasting organization, sending samples / products in China and neighboring Asian countries (Hong Kong, Singapore, Japan, Korea etc ...) .
  • "READY TO SELL" competitive advantage directly in China for your business
  • No tax: Stored goods Taxation only when really sold
  • Chinese Labels: Quick management for Chinese product labels
  • Simplified management of your distributors directly in China and multi / distributors with a single national stock
  • Pay per Use for your warehouse in China
  • Showroom activity for buyers product overview and tasting
  • Transparent management of all steps
  • Monitoring direct from your own country

Choose "the PLUS" more appropriate for your distribution needs in China and Asia!

For information or contact: [email protected]

Highlights
Friday, 14 December 2018
HOT NEWS

My China B2B Newsletter

Enter your Email


Preview

My CHINA B2B Blog

My China B2B Blog: Culture, Society, Finance, Business, Business to Business

Nov 10
2010

Economy Biopharmaceutical firms told better quality control holds key to global growth in China

Posted by: My China B2B

My China B2B

The country's biopharmaceutical industry needs to tighten quality control measures and maintain its own standards to overcome barriers in overseas markets as well as secure an emerging domestic one, officials have said.

"Quality problems in food and pharmaceutical products will have a lethal effect on consumer confidence. The melamine-tainted milk scandal provided a negative example," Liu Zhanglin, deputy head of the China Chamber of Commerce for the Import and Export of Medicines and Health Products, said at the Cross-Straits BioPharmaceutical Forum on Saturday.

The global herbal product market alone is now worth nearly $83 billion, with a steady year-on-year growth rate ranging from 3 to 12 percent, industry figures showed.

The Chinese government has also listed the development of the biopharmaceutical industry as a main task in the 12th Five-Year Plan (2011-2015).

"In China, 80 percent of industry output was gained through exports, but these were mainly low-priced raw materials," Liu said.

"Meanwhile, the United States and other Western countries are raising the threshold of biopharmaceutical products by setting technological barriers."

Raw materials provided by China had accounted for half of the amount in some target markets including the United States, Europe and Japan, Liu said.

The export volume of traditional Chinese medicine (TCM) alone experienced growth for 10 consecutive years with an average increase of more than 16 percent, but it was worth just $91 million in the first six months of 2010.

In comparison, the export volume of Western medicine was 13 times larger.

Many restrictions in Western markets have also threatened China's TCM products. These include technical barriers involving heavy metals, pesticide residues and microbial limits. The "green barriers" of importing countries have blocked more than 60 percent of the TCM products, industry figures showed.

Liu admitted that the adulteration and overuse of pesticide was responsible for some of the problems in the industry. He urged all stakeholders to be self-disciplined in preventing these but he also pointed out that the standards adopted by Western countries may not be totally applicable for Chinese cases.

"For example, some of the ingredients used in traditional Chinese medicine are more likely to retain heavy metal elements. It may not meet Western standards, but it still has a good effect on patients," Liu said.

The Ministry of Commerce has entrusted his organization to draft seven standards for biomedical production, while another 13 were under discussion with industry players, he said.

"In order to achieve sustainable development, the industry should look more at the potential of the domestic market and emerging markets," he said.

With an aging society and an improving universal healthcare system, China's biomedical industry is expected to be worth 4 trillion yuan ($600 billion) by the next decade, exceeding that of Japan and Europe to become the world's second-largest pharmaceutical market.

Exports to the Association of Southeast Asian Nations (ASEAN) area recorded 41.8 percent growth after the launch of the China-ASEAN Free Trade Area in January.

Chen Chei-hsiang, director of the Biotechnology and Pharmaceutical Industries Program Office in Taiwan, said both sides of the Straits can achieve win-win cooperation in the biopharmaceutical industry.